PB 6 of 2015
National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1)
National Health Act 1953
I, ANDREW RINTOUL, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated 23 January 2015
ANDREW RINTOUL
Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
Part 1 Preliminary
1 Name of Determination
(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1).
(2) This Determination may also be cited as PB 6 of 2015.
2 Commencement
This Determination commences on 1 February 2015.
3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1 Amendments
(Section 3)
[1] Schedule 1, after item dealing with Ciclesonide
Omit
Cidofovir
[2] Schedule 2, after item dealing with Doxorubicin
Omit
Doxorubicin – Peglyated Liposomal
Insert
Doxorubicin – Pegylated Liposomal
[3] Schedule 2, after item dealing with Duloxetine
Omit
Electrolyte replacement (oral)
Insert
Electrolyte Replacement, Oral
[4] Schedule 2, after item dealing with Thyroxine
Omit
Ticlopidine
